Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database - PubMed
2 hours ago
- #Thyroid cancer
- #Pharmacovigilance
- #GLP-1 receptor agonists
- This study evaluates the safety profile of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) by analyzing reports from the European pharmacovigilance database, focusing on thyroid cancer-related adverse events.
- The analysis included 34,956 individual case safety reports for drugs like semaglutide, liraglutide, and tirzepatide from January 2022 to September 2024, with most involving adult and elderly female patients.
- Key reported adverse events categories were gastrointestinal disorders, general disorders, administration site conditions, and injury or poisoning complications.
- Disproportionality analysis indicated semaglutide had a lower reporting probability for thyroid cancer events compared to tirzepatide, but sensitivity analysis showed no consistent risk signals across different therapeutic groups.
- The findings are cautious due to database limitations, and further studies are recommended to clarify any causal link between GLP-1 RAs and thyroid cancer.